Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

PMID:
30301790
2.

Minimum tillage and organic fertilization for the sustainable management of Brassica carinata A. (Braun) in the Mediterranean environment.

Debiase G, Traversa A, Montemurro F, Mastrangelo M, Fiore A, Ventrella G, Brunetti G.

Environ Sci Pollut Res Int. 2018 Sep 29. doi: 10.1007/s11356-018-3244-z. [Epub ahead of print]

PMID:
30269278
3.

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.

Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F.

Breast. 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004. Epub 2018 Jul 12.

PMID:
30092500
4.

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study.

Galizia D, Milani A, Geuna E, Martinello R, Cagnazzo C, Foresto M, Longo V, Berchialla P, Solinas G, Calori A, Grasso B, Volpone C, Bertola G, Parola G, Tealdi G, Giuliano PL, Ballari AM, Aglietta M, Montemurro F.

Cancer Med. 2018 Sep;7(9):4339-4344. doi: 10.1002/cam4.1687. Epub 2018 Jul 20.

5.

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.

Marchiò C, Dell'Orto P, Annaratone L, Geyer FC, Venesio T, Berrino E, Verdun di Cantogno L, Garofoli A, Rangel N, Casorzo L, dell'Aglio C, Gugliotta P, Trisolini E, Beano A, Pietribiasi F, Orlassino R, Cassoni P, Pich A, Montemurro F, Mottolese M, Vincent-Salomon A, Penault-Llorca F, Medico E, Ng CKY, Viale G, Sapino A.

Am J Surg Pathol. 2018 Sep;42(9):1190-1200. doi: 10.1097/PAS.0000000000001100.

6.

Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey.

Bonotto M, Basile D, Gerratana L, Pelizzari G, Bartoletti M, Vitale MG, Fanotto V, Lisanti C, Mansutti M, Minisini AM, Aprile G, De Laurentiis M, Montemurro F, Del Mastro L, Puglisi F.

Breast. 2018 Aug;40:45-52. doi: 10.1016/j.breast.2018.04.011. Epub 2018 Apr 19.

PMID:
29679936
7.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
8.

Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.

Giannone G, Milani A, Ghisoni E, Genta S, Mittica G, Montemurro F, Valabrega G.

Breast. 2018 Apr;38:160-164. doi: 10.1016/j.breast.2018.01.006. Epub 2018 Feb 3.

PMID:
29413403
9.

Cardiac tissue regeneration: A preliminary study on carbon-based nanotubes gelatin scaffold.

Cabiati M, Vozzi F, Gemma F, Montemurro F, De Maria C, Vozzi G, Domenici C, Del Ry S.

J Biomed Mater Res B Appl Biomater. 2017 Dec 5. doi: 10.1002/jbm.b.34056. [Epub ahead of print]

PMID:
29206329
10.

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, Montemurro F, Nisticò C, Gasparro S, Cognetti F.

Future Oncol. 2017 Dec;13(30):2791-2797. doi: 10.2217/fon-2017-0336. Epub 2017 Nov 28.

PMID:
29182361
11.

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

Martel S, Poletto E, Ferreira AR, Lambertini M, Sottotetti F, Bertolini I, Montemurro F, Bernardo A, Risi E, Zanardi E, Ziliani S, Mura S, Dellepiane C, Del Mastro L, Minisini AM, Puglisi F.

Breast. 2018 Feb;37:142-147. doi: 10.1016/j.breast.2017.11.004. Epub 2017 Nov 21.

PMID:
29161652
12.

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases.

Siravegna G, Geuna E, Mussolin B, Crisafulli G, Bartolini A, Galizia D, Casorzo L, Sarotto I, Scaltriti M, Sapino A, Bardelli A, Montemurro F.

ESMO Open. 2017 Oct 9;2(4):e000253. doi: 10.1136/esmoopen-2017-000253. eCollection 2017.

13.

Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function.

Gulluni F, Martini M, De Santis MC, Campa CC, Ghigo A, Margaria JP, Ciraolo E, Franco I, Ala U, Annaratone L, Disalvatore D, Bertalot G, Viale G, Noatynska A, Compagno M, Sigismund S, Montemurro F, Thelen M, Fan F, Meraldi P, Marchiò C, Pece S, Sapino A, Chiarle R, Di Fiore PP, Hirsch E.

Cancer Cell. 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.

14.

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F.

Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8.

15.

Treating breast cancer with cell-based approaches: an overview.

Gallo S, Sangiolo D, Carnevale Schianca F, Aglietta M, Montemurro F.

Expert Opin Biol Ther. 2017 Oct;17(10):1255-1264. doi: 10.1080/14712598.2017.1356816. Epub 2017 Jul 20. Review.

PMID:
28728493
16.

A computer-aided diagnosis (CAD) scheme for pretreatment prediction of pathological response to neoadjuvant therapy using dynamic contrast-enhanced MRI texture features.

Giannini V, Mazzetti S, Marmo A, Montemurro F, Regge D, Martincich L.

Br J Radiol. 2017 Aug;90(1077):20170269. doi: 10.1259/bjr.20170269. Epub 2017 Jul 14.

17.

Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy.

Cont NT, Maggiorotto F, Martincich L, Rivolin A, Kubatzki F, Sgandurra P, Marocco F, Magistris A, Gatti M, Balmativola D, Montemurro F, Sapino A, Ponzone R.

Breast Cancer Res Treat. 2017 Aug;165(1):85-95. doi: 10.1007/s10549-017-4312-7. Epub 2017 May 28.

PMID:
28553683
18.

Trastuzumab emtansine in HER2-positive metastatic breast cancer.

Montemurro F.

Lancet Oncol. 2017 Jun;18(6):696-697. doi: 10.1016/S1470-2045(17)30303-0. Epub 2017 May 16. No abstract available.

PMID:
28526537
19.

Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium.

Zucchini G, Montemurro F.

Expert Opin Pharmacother. 2017 Jun;18(9):853-855. doi: 10.1080/14656566.2017.1328500. Epub 2017 May 19.

PMID:
28481697
20.

Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.

Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L.

Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11.

PMID:
28479052
21.

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G.

Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21.

22.

Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).

Di Maio M, Bruzzi P, Perrone F, Torri V, Montemurro F, Tiseo M, Vasile E.

ESMO Open. 2016 Dec 12;1(6):e000109. doi: 10.1136/esmoopen-2016-000109. eCollection 2016. Review.

23.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.

Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10.

PMID:
27951450
24.

New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.

Martinello R, Genta S, Galizia D, Geuna E, Milani A, Zucchini G, Valabrega G, Montemurro F.

Expert Opin Pharmacother. 2016 Nov;17(16):2179-2189. Epub 2016 Sep 27. Review.

25.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P.

Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29.

PMID:
27358383
26.

Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer.

Ponzone R, Ruatta F, Gatti M, Castellano I, Geuna E, Amato G, Kubatzki F, Sgandurra P, Sapino A, Montemurro F.

Cancer Treat Rev. 2016 Jul;48:1-7. doi: 10.1016/j.ctrv.2016.05.005. Epub 2016 May 24. Review.

PMID:
27262016
27.

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.

Gori S, Inno A, Rossi V, Turazza M, Fiorio E, Fabi A, Bisagni G, Foglietta J, Santini D, Pavese I, Pellegrino A, Zambelli A, Vici P, Leonardi V, Barni S, Saracchini S, Bogina G, Marchetti F, Duranti S, Lunardi G, Montemurro F.

PLoS One. 2016 May 25;11(5):e0156221. doi: 10.1371/journal.pone.0156221. eCollection 2016.

28.

Agricultural by-products with bioactive effects: A multivariate approach to evaluate microbial and physicochemical changes in a fresh pork sausage enriched with phenolic compounds from olive vegetation water.

Fasolato L, Carraro L, Facco P, Cardazzo B, Balzan S, Taticchi A, Andreani NA, Montemurro F, Martino ME, Di Lecce G, Toschi TG, Novelli E.

Int J Food Microbiol. 2016 Jul 2;228:34-43. doi: 10.1016/j.ijfoodmicro.2016.04.003. Epub 2016 Apr 5.

PMID:
27088870
29.

Changing paradigms in the treatment of hormone-receptor positive advanced breast cancer.

Filippi R, Montemurro F.

Expert Opin Pharmacother. 2016 Jun;17(8):1039-41. doi: 10.1517/14656566.2016.1174213. Epub 2016 Apr 14. No abstract available.

PMID:
27042879
30.

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F.

Oncotarget. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480.

31.

Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.

Martinello R, Milani A, Geuna E, Zucchini G, Aversa C, Nuzzo A, Montemurro F.

Expert Opin Investig Drugs. 2016;25(4):393-403. doi: 10.1517/13543784.2016.1153063. Epub 2016 Feb 29. Review.

PMID:
26863927
32.

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.

Garrone O, Montemurro F, Saggia C, La Verde N, Vandone AM, Airoldi M, De Conciliis E, Donadio M, Lucio F, Polimeni MA, Oletti MV, Giacobino A, Merlano MC.

Springerplus. 2016 Jan 21;5:59. doi: 10.1186/s40064-016-1700-0. eCollection 2016.

33.

Breast cancer in BRCA mutation carriers: medical treatment.

Milani A, Geuna E, Zucchini G, Aversa C, Martinello R, Montemurro F.

Minerva Ginecol. 2016 Oct;68(5):557-65. Epub 2016 Jan 22. Review.

PMID:
26799758
34.

Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.

Montemurro F, Mittica G, Cagnazzo C, Longo V, Berchialla P, Solinas G, Culotta P, Martinello R, Foresto M, Gallizioli S, Calori A, Grasso B, Volpone C, Bertola G, Parola G, Tealdi G, Giuliano PL, Aglietta M, Ballari AM.

JAMA Oncol. 2016 Apr;2(4):445-52. doi: 10.1001/jamaoncol.2015.4720.

35.

p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.

Bisaro B, Sciortino M, Colombo S, Camacho Leal MP, Costamagna A, Castellano I, Montemurro F, Rossi V, Valabrega G, Turco E, Defilippi P, Cabodi S.

Oncotarget. 2016 Jan 26;7(4):4442-53. doi: 10.18632/oncotarget.6710.

36.

AKT signaling in ERBB2-amplified breast cancer.

Carmona FJ, Montemurro F, Kannan S, Rossi V, Verma C, Baselga J, Scaltriti M.

Pharmacol Ther. 2016 Feb;158:63-70. doi: 10.1016/j.pharmthera.2015.11.013. Epub 2015 Dec 2. Review.

37.

Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.

Montemurro F, Del Mastro L, De Laurentiis M, Puglisi F.

Expert Rev Anticancer Ther. 2016;16(2):211-8. doi: 10.1586/14737140.2016.1128327. Epub 2015 Dec 23. Review.

PMID:
26634955
38.

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.

Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, Yap TA, Kaye SB, De Bono JS, Molife LR, Banerji U.

Br J Cancer. 2015 Dec 1;113(11):1541-7. doi: 10.1038/bjc.2015.373. Epub 2015 Nov 10.

39.

Genipin diffusion and reaction into a gelatin matrix for tissue engineering applications.

Montemurro F, De Maria C, Orsi G, Ghezzi L, Tinè MR, Vozzi G.

J Biomed Mater Res B Appl Biomater. 2017 Apr;105(3):473-480. doi: 10.1002/jbm.b.33569. Epub 2015 Nov 5.

PMID:
26540388
40.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

Arpino G, Michelotti A, Truini M, Montemurro F, Russo S, Palumbo R, Zamagni C, Latorre A, Bruzzese D, Riccardi F, De Laurentiis M, Beano A, Biganzoli L, Zaniboni A, Laudadio L, Malagoli M, Bilancia D, Schettini F, Giuliano M, Cazzaniga ME, De Placido S.

J Cancer Res Clin Oncol. 2016 Mar;142(3):669-78. doi: 10.1007/s00432-015-2033-z. Epub 2015 Aug 25.

PMID:
26531187
41.

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.

Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L.

Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22.

42.

The influence of mesh topology in the abdominal wall repair process.

De Maria C, Burchielli S, Salvadori C, Santoro V, Montemurro F, Orsi G, Vozzi G.

J Biomed Mater Res B Appl Biomater. 2016 Aug;104(6):1220-8. doi: 10.1002/jbm.b.33468. Epub 2015 Jun 19.

PMID:
26097153
43.

Clinical utility of exemestane in the treatment of breast cancer.

Zucchini G, Geuna E, Milani A, Aversa C, Martinello R, Montemurro F.

Int J Womens Health. 2015 May 27;7:551-63. doi: 10.2147/IJWH.S69475. eCollection 2015. Review.

44.

Minimum Bactericidal Concentration of Phenols Extracted from Oil Vegetation Water on Spoilers, Starters and Food-Borne Bacteria.

Fasolato L, Cardazzo B, Balzan S, Carraro L, Taticchi A, Montemurro F, Novelli E.

Ital J Food Saf. 2015 May 28;4(2):4519. eCollection 2015 May 28.

45.

Linifanib: current status and future potential in cancer therapy.

Aversa C, Leone F, Zucchini G, Serini G, Geuna E, Milani A, Valdembri D, Martinello R, Montemurro F.

Expert Rev Anticancer Ther. 2015 Jun;15(6):677-87. doi: 10.1586/14737140.2015.1042369. Epub 2015 May 2. Review.

PMID:
25936222
46.

Adjuvant ovarian suppression in premenopausal breast cancer.

Montemurro F, Perrone F, Geuna E.

N Engl J Med. 2015 Apr 23;372(17):1672-3. doi: 10.1056/NEJMc1502618. No abstract available.

PMID:
25901438
47.

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.

Alajati A, Guccini I, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, Montani E, Rinaldi A, Montemurro F, Catapano C, Bertoni F, Alimonti A.

Cell Rep. 2015 Apr 28;11(4):564-76. doi: 10.1016/j.celrep.2015.03.044. Epub 2015 Apr 16.

48.

A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients.

Valabrega G, Berrino G, Milani A, Aglietta M, Montemurro F.

Breast J. 2015 May-Jun;21(3):241-5. doi: 10.1111/tbj.12398. Epub 2015 Mar 15.

PMID:
25772707
49.

HER2-positive metastatic breast cancer: a changing scenario.

Mustacchi G, Biganzoli L, Pronzato P, Montemurro F, Dambrosio M, Minelli M, Molteni L, Scaltriti L.

Crit Rev Oncol Hematol. 2015 Jul;95(1):78-87. doi: 10.1016/j.critrevonc.2015.02.002. Epub 2015 Feb 20. Review.

PMID:
25748080
50.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators.

Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.

PMID:
25740286

Supplemental Content

Loading ...
Support Center